-
公开(公告)号:NO20012219L
公开(公告)日:2001-06-13
申请号:NO20012219
申请日:2001-05-04
Applicant: BASF AG
Inventor: DOYLE KEVIN J , RAFFERTY PAUL , STEELE ROBERT WILLIAM , WILKINS DAVID J , HOCKLEY MICHAEL , ARNOLD LEE DANIEL , ERICSSON ANNA M
IPC: A61K31/416 , A61K31/4162 , A61K31/4427 , A61K31/4433 , A61K31/4439 , A61P1/04 , A61P1/16 , A61P5/14 , A61P7/10 , A61P9/00 , A61P9/10 , A61P11/00 , A61P15/08 , A61P17/02 , A61P17/06 , A61P19/02 , A61P19/08 , A61P27/00 , A61P27/06 , A61P35/00 , A61P37/00 , A61P43/00 , C07D231/54 , C07D401/04 , C07D401/12 , C07D403/12 , C07D409/04 , C07D413/04 , C07D417/12 , C07D491/04 , C07D491/048 , C07D495/04 , A61K31/415
Abstract: This invention relates to certain 3-aryl or 3-heteroaryl pyrazoles with 4,5(3,4)-bicyclic ring fusion which are inhibitors of protein kinase activity, of which some are novel compounds, to pharmaceutical compositions containing these pyrazoles and to processes for preparing these pyrazoles.
-
公开(公告)号:ID24653A
公开(公告)日:2000-07-27
申请号:ID991048
申请日:1998-03-09
Applicant: BASF AG
Inventor: CALDERWOOD DAVID JOHN , JOHNSTON DAVID NORMAN , RAFFERTY PAUL , TWIGGER HELEN LOUISE , MUNSCHAUER RAINER , ARNOLD LEE
IPC: A61K31/519 , A61P35/00 , A61P37/02 , A61P43/00 , C07D487/04 , A61K31/505
Abstract: Compounds of formula I including pharmaceutically acceptable salts thereof in which R1 represents hydrogen, 2-phenyl-1,3-dioxan-5-yl, a C1-6 alkyl group, a C3-8 cycloalkyl group, a C5-7 cycloalkenyl group or an (optionally substituted phenyl)C1-6 alkyl group wherein the alkyl, cycloalkyl and cycloalkenyl groups are optionally substituted by one or more groups of formula ORA in which RA represents H or a C1-6 alkyl group provided that a group of formula ORA is not located on the carbon attached to nitrogen; R2 represents hydrogen, a C1-6 alkyl group, a C3-8 cycloalkyl group, halo, hydroxy, an (optionally substituted phenyl)C1-6 alkyl group, optionally substituted phenyl or R4; and R3 represents a group of formula (a) in which the phenyl ring is additionally optionally substituted and A represents NH, O, NHSO2, SO2NH, a C1-4 alkylene chain, NHCO, NHCO2, CONH, NHCONH, CO2 or S(O)p in which p is 0, 1 or 2, or A is absent and R5 is attached directly to the phenyl ring; and R5 represents optionally substituted phenyl and, additionally, when A is absent R5 represents a) a phthalimido group optionally substituted by halo or b) a pyrazolylamino group in which the pyrazole ring is optionally substituted by one or more of the following: hydroxy or optionally substituted phenyl; R4 represents a heterocyclic group; are described which are useful in treating proliferative diseases and disorders of the immune system in mammals. Processes to prepare these compounds and pharmaceutical compositions containing these compound are also described.
-
公开(公告)号:BG103785A
公开(公告)日:2000-06-30
申请号:BG10378599
申请日:1999-10-07
Applicant: BASF AG
Inventor: CALDERWOOD DAVID J , JOHNSTON DAVID N , RAFFERTY PAUL , TWIGGER HELEN L , MUNSCHAUER RAINER , ARNOLD LEE
IPC: A61K31/519 , A61P35/00 , A61P37/02 , A61P43/00 , C07D487/04 , A61K31/505
Abstract: The compounds are useful for the treatment of proliferative diseases and diseases of the immune system in mammals, including their pharmaceutically acceptable salts. The compounds have the formula where R1 means hydrogen, 2-phenyl-1,3-dioxan-5-yl, C1-6-alkyl group, C3-8-cycloalkyl group, C5-7-cycloalkenyl group or (optionally substituted phenyl) C1-6-alkyl where the alkyl, cycloalkyl and cycloalkenyl group are optionally substituted by one or more groups with the formula ORA where RA means hydrogen or C1-6-alkyl group provided that the group with formula ORA is not positioned at the carbon atom adjuncted to the nitrogen; R2 means hydrogen, C1-6-alkyl group, C3-8-cycloalkyl group, halogen, hydroxy (optionally substituted phenyl)-C1-6-alkyl, optionally substituted phenyl or R4; and R3 means a group with formula (a) where the phenyl ring is optionally additionally substituted and A means NH, O, NHSO2, SO2NH, C1-4-alkylen residue, NHCO, NHCO2, CONH, NHCONH, CO2 or S(O)p where p has the value of 0,1 or 2, or A is absent and R5 is adjuncted directly to the phenyl ring; and R5 optionally means substituted phenyl, and in addition when A is absent, then R5 means phthalimidogroup optionally substituted with halogen, or pyrazolylaminogroup where the pyrazol ring is optionally substituted with one or more of the following groups: hydroxy or optionally substituted phenyl; R4 is heterocyclic group. The invention also relates to methods for the preparation of these compounds and pharmaceutical compositions containing them. 30 claims
-
公开(公告)号:CZ9903283A3
公开(公告)日:2000-03-15
申请号:CZ328399
申请日:1998-03-09
Applicant: BASF AG
Inventor: CALDERWOOD DAVID JOHN , JOHNSTON DAVID NORMAN , RAFFERTY PAUL , TWIGGER HELEN LOUISE , MUNSCHAUER RAINER , ARNOLD LEE
IPC: A61K31/505 , A61P37/00 , C07D209/00 , C07D239/00 , C07D487/04
-
公开(公告)号:CZ328399A3
公开(公告)日:2000-03-15
申请号:CZ328399
申请日:1998-03-09
Applicant: BASF AG
Inventor: CALDERWOOD DAVID JOHN , JOHNSTON DAVID NORMAN , RAFFERTY PAUL , TWIGGER HELEN LOUISE , MUNSCHAUER RAINER , ARNOLD LEE
IPC: A61K31/505 , A61P37/00 , C07D209/00 , C07D239/00 , C07D487/04
-
公开(公告)号:TR9902301T2
公开(公告)日:1999-12-21
申请号:TR9902301
申请日:1998-03-09
Applicant: BASF AG
Inventor: CALDERWOOD DAVID JOHN , JOHNSTON DAVID NORMAN , RAFFERTY PAUL , TWIGGER HELEN LOUISE , MUNSCHAUER DR RAINER , ARNOLD LEE
IPC: A61K31/519 , A61P35/00 , A61P37/02 , A61P43/00 , C07D487/04
CPC classification number: C07D487/04
-
公开(公告)号:NO994509D0
公开(公告)日:1999-09-17
申请号:NO994509
申请日:1999-09-17
Applicant: BASF AG
Inventor: CALDERWOOD DAVID JOHN , JOHNSTON DAVID NORMAN , RAFFERTY PAUL , TWIGGER HELEN LOUISE , MUNSCHAUER RAINER , ARNOLD LEO
IPC: A61K31/519 , A61P35/00 , A61P37/02 , A61P43/00 , C07D487/04 , C07D
Abstract: Compounds of formula I including pharmaceutically acceptable salts thereof in which R1 represents hydrogen, 2-phenyl-1,3-dioxan-5-yl, a C1-6 alkyl group, a C3-8 cycloalkyl group, a C5-7 cycloalkenyl group or an (optionally substituted phenyl)C1-6 alkyl group wherein the alkyl, cycloalkyl and cycloalkenyl groups are optionally substituted by one or more groups of formula ORA in which RA represents H or a C1-6 alkyl group provided that a group of formula ORA is not located on the carbon attached to nitrogen; R2 represents hydrogen, a C1-6 alkyl group, a C3-8 cycloalkyl group, halo, hydroxy, an (optionally substituted phenyl)C1-6 alkyl group, optionally substituted phenyl or R4; and R3 represents a group of formula (a) in which the phenyl ring is additionally optionally substituted and A represents NH, O, NHSO2, SO2NH, a C1-4 alkylene chain, NHCO, NHCO2, CONH, NHCONH, CO2 or S(O)p in which p is 0, 1 or 2, or A is absent and R5 is attached directly to the phenyl ring; and R5 represents optionally substituted phenyl and, additionally, when A is absent R5 represents a) a phthalimido group optionally substituted by halo or b) a pyrazolylamino group in which the pyrazole ring is optionally substituted by one or more of the following: hydroxy or optionally substituted phenyl; R4 represents a heterocyclic group; are described which are useful in treating proliferative diseases and disorders of the immune system in mammals. Processes to prepare these compounds and pharmaceutical compositions containing these compound are also described.
-
公开(公告)号:CA2304466A1
公开(公告)日:1999-04-15
申请号:CA2304466
申请日:1998-10-06
Applicant: BASF AG
Inventor: HOCKLEY MICHAEL , ARNOLD LEE D , TURNER ALLYSON , BARLOZZARI TERESA , RAFFERTY PAUL , XU YAJUN
IPC: C07D231/54 , A61K31/415 , A61K31/416 , A61K31/4427 , A61K31/4439 , A61P1/02 , A61P1/04 , A61P9/00 , A61P9/10 , A61P15/00 , A61P17/06 , A61P19/00 , A61P19/02 , A61P27/02 , A61P35/00 , A61P43/00 , C07D401/04 , C07D403/04
Abstract: Chemical compounds that are derivatives of indeno1,2-c!pyrazole are inhibitors of tyrosine kinase activity. Several of the tyrosine kinases, whose activity is inhibited by these chemical compounds, are involved in angiogenic processes. Thus, these chemical compounds can ameliorate disease states where angiogenesis or endothelial cell proliferation is a factor. Compounds of this invention also inhibit the induction of vascular hyperpermeability and the associated formation of edema, ascites, and exudates.
-
公开(公告)号:DE69815317D1
公开(公告)日:2003-07-10
申请号:DE69815317
申请日:1998-03-09
Applicant: BASF AG
Inventor: CALDERWOOD JOHN , JOHNSTON NORMAN , RAFFERTY PAUL , TWIGGER LOUISE , MUNSCHAUER RAINER , ARNOLD LEE
IPC: A61K31/519 , A61P35/00 , A61P37/02 , A61P43/00 , C07D487/04 , A61K31/505
Abstract: Compounds of formula I including pharmaceutically acceptable salts thereof in which R1 represents hydrogen, 2-phenyl-1,3-dioxan-5-yl, a C1-6 alkyl group, a C3-8 cycloalkyl group, a C5-7 cycloalkenyl group or an (optionally substituted phenyl)C1-6 alkyl group wherein the alkyl, cycloalkyl and cycloalkenyl groups are optionally substituted by one or more groups of formula ORA in which RA represents H or a C1-6 alkyl group provided that a group of formula ORA is not located on the carbon attached to nitrogen; R2 represents hydrogen, a C1-6 alkyl group, a C3-8 cycloalkyl group, halo, hydroxy, an (optionally substituted phenyl)C1-6 alkyl group, optionally substituted phenyl or R4; and R3 represents a group of formula (a) in which the phenyl ring is additionally optionally substituted and A represents NH, O, NHSO2, SO2NH, a C1-4 alkylene chain, NHCO, NHCO2, CONH, NHCONH, CO2 or S(O)p in which p is 0, 1 or 2, or A is absent and R5 is attached directly to the phenyl ring; and R5 represents optionally substituted phenyl and, additionally, when A is absent R5 represents a) a phthalimido group optionally substituted by halo or b) a pyrazolylamino group in which the pyrazole ring is optionally substituted by one or more of the following: hydroxy or optionally substituted phenyl; R4 represents a heterocyclic group; are described which are useful in treating proliferative diseases and disorders of the immune system in mammals. Processes to prepare these compounds and pharmaceutical compositions containing these compound are also described.
-
公开(公告)号:AU762992B2
公开(公告)日:2003-07-10
申请号:AU1909100
申请日:1999-11-04
Applicant: BASF AG
Inventor: DOYLE KEVIN J , RAFFERTY PAUL , STEELE ROBERT W , WILKINS DAVID J , HOCKLEY MICHAEL , ARNOLD LEE D , ERICSSON ANNA M
IPC: A61K31/416 , A61K31/4162 , A61K31/4427 , A61K31/4433 , A61K31/4439 , A61P1/04 , A61P1/16 , A61P5/14 , A61P7/10 , A61P9/00 , A61P9/10 , A61P11/00 , A61P15/08 , A61P17/02 , A61P17/06 , A61P19/02 , A61P19/08 , A61P27/00 , A61P27/06 , A61P35/00 , A61P37/00 , A61P43/00 , C07D231/54 , C07D401/04 , C07D401/12 , C07D403/12 , C07D409/04 , C07D413/04 , C07D417/12 , C07D491/04 , C07D491/048 , C07D495/04 , A61K31/415 , A61K31/425 , A61K31/44 , A61K31/445 , A61K31/505 , A61K31/53 , A61P29/00
Abstract: This invention relates to certain 3-aryl or 3-heteroaryl pyrazoles with 4,5(3,4)-bicyclic ring fusion which are inhibitors of protein kinase activity, of which some are novel compounds, to pharmaceutical compositions containing these pyrazoles and to processes for preparing these pyrazoles.
-
-
-
-
-
-
-
-
-